MOUNTAIN VIEW, Calif., Jan. 26, 2012 /PRNewswire/ -- Pinpoint Genomics, Inc. today announced the publication of key data relating to its Pinpoint Dx Lung Assay in the journal The Lancet.
The Pinpoint Dx Lung Assay is a molecular diagnostic assay that differentiates between patients at high, intermediate or low risk of early death after surgery to remove a non-squamous, non-small cell lung cancer, the most common form of lung cancer.
The report in The Lancet describes the development of the assay based on specimens from 361 patients who underwent surgery at the University of California, San Francisco (UCSF), as well as the results of the two largest independent, blinded studies to evaluate the clinical validity of a multi-gene molecular diagnostic assay for early stage lung cancer. The two validation studies, conducted by the Kaiser Permanente Division of Research and the China Clinical Trials Consortium, involved 433 patients from northern California and 1,006 patients from several leading cancer centers in China, respectively.
About Pinpoint Genomics and the Pinpoint Dx Lung Assay
Pinpoint Genomics, Inc. is a privately held cancer company focused on the development and commercialization of molecular assays and genomic-based clinical laboratory services to provide individualized information to patients and clinicians.
The frequent recurrence of early stage non-small cell lung cancer (NSCLC) is generally due to metastatic disease that is undetected at the time of surgery to remove the tumor. Despite the high rate of recurrence, many early stage patients do not receive any additional therapy directed against this occult disease. The Pinpoint Dx Lung Assay is a multigene expression test that has been developed to identify those patients with a high likelihood of death within five years following surgery to remove early-stage tumors.
The Pinpoint Dx Lung assay is run on surgical specimens that undergo routine handling by pathology laboratories, making it immediately available to virtually all patients, and is offered through Pinpoint's Clinical Laboratory Improvement Amendment-certified laboratory in Mountain View, California. "It is the first step in our vision to bring powerful new tools to the oncology community," said David Berryman, Chief Executive Officer, Pinpoint Genomics.
Pinpoint Genomics is also developing additional assays for patients with lung and other cancers. The company is based in Mountain View, California. For more information, please contact www.pinpointgenomics.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company's lung cancer studies, prospects for its next generation cancer diagnostic programs; the availability of its planned next generation products; the ability of the company's tests to impact clinical practice, and reimbursement for its products. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the results of clinical and developmental studies; the applicability of clinical study results to actual outcomes; our ability to develop and commercialize new tests and the timing thereof; unanticipated costs or delays in research and development efforts; the risk that we may not obtain or maintain sufficient levels of reimbursement for our existing tests and any future tests we may develop; our ability to compete in the marketplace; the risks and uncertainties associated with the regulation of our tests by the State of California, the FDA or other agencies.
The Pinpoint Genomics logo and Pinpoint Dx Lung Assay are trademarks of Pinpoint Genomics, Inc.
SOURCE Pinpoint Genomics, Inc.
